[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Benef](https://github.com/mm80843/T3.5/tree/pages/docs/Benef/index.md) >> Individual ID:PBN__Benef_578 

# __Faster vaccine development__

## Articles mentionning this Benefit

* [Emerging Technologies to Combat the COVID-19 Pandemic](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_116.md)

## Category to which it belongs

* [Expanded vaccination capabilities lead to improved healthcare capacity, equitable distribution, and enhanced response and technological capabilities.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_31.md)

## Description of actual returns pertaining to this benefit

* [Private investors can benefit from investing in molecular technologies by participating in the production and distribution of vaccines and contributing to public health.](https://github.com/mm80843/T3.5/blob/pages/BenefReturn/PBN__BenefReturn_633.md)

## Name of the Benefit

Accelerated production of vaccines

## Risks which can benefit from this action

* [Utilization of molecular technologies](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_586.md)

## Stakeholders benefitting from this Benefit

* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)
* [Population](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_81.md)

